WuXi Biologics Drug Substance Manufacturing Facility Passes FDA Pre-License Inspection

Editor’s Take: WuXi has been tallying certifications and clearances for its China facilities in the middle months of 2026.

WuXi Biologics’ MFG8 drug substance manufacturing facility in Hebei, China successfully passed U.S. FDA Pre-License Inspection (PLI). This benchmark supports commercial manufacturing for what the global CRDMO calls a potential “blockbuster” autoimmune therapy.

Exactly what the therapy is has not been disclosed by WuXi Biologics. In acknowledging the inspection, CEO Chris Chen, PhD, said WuXi’s high-quality manufacturing capabilities will help bring the therapy to patients.

Reaction to FDA Inspection

“MFG8’s successful PLI pass is a strong testament to WuXi Biologics’ commitment to global quality and compliance standards,” Chen said. “This reflects sustained investment in a world-class quality system and proven capability to support partners in advancing global commercial manufacturing … WuXi Biologics will continue to empower global partners with a reliable quality system and accelerate the delivery of innovative biologics.”

WuXi characterized MFG8 as an important part of its global manufacturing network. The facility is equipped with 12 4000-L single-use bioreactors. The company can accordingly scale out to offer commercial manufacturing from anywhere from 4000 to 20,000 L.

WuXi’s Regulatory Record

Within the last month, four other WuXi Biologics sites have garnered regulatory wins. Two manufacturing facilities and a packaging center, all in WuXi, China, got good manufacturing practice (GMP) certification from Brazil’s ANVISA. And the company’s Suzhou Biosafety Testing Center passed a GMP inspection by the European Medicines Agency (EMA).

For the FDA inspection in Hebei, which took seven days, three inspectors conducted quality management and drug substance manufacturing checks. Successful passing meant no blemishes to WuXi Biologics’ 100% pass rate in FDA PLIs to date.

Not counting the most recent certifications, WuXi Biologics as of the end of 2025 passed 46 regulatory inspections. These include 22 by either the FDA or EMA.